Testmiljö
Observera att detta är en testmiljö för utveckling som inte ska användas som underlag för klinisk bedömning. Besök Janusmed här: https://janusmed.se

11/21/2024

Janusmed kön och genus

Janusmed kön och genus – Duac

Janusmed kön och genus är ett kunskapsstöd som tillhandahåller information om köns- och genusaspekter på läkemedelsbehandling. Kunskapsstödet är avsedd främst för hälso- och sjukvårdspersonal. Texterna är generella och ska inte ses som behandlingsriktlinjer. Det är alltid behandlande läkare som ansvarar för patientens medicinering.

För att komma till startsidan för Janusmed kön och genus och för att göra sökningar klicka här.

Tillbaka till index
B B
B B

Bensoylperoxid Testmiljö

Bensoylperoxid

Klass : B

Visa all info

Skriv ut

Kontakta oss

  1. Lello J, Pearl A, Arroll B, Yallop J, Birchall NM. Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J. 1995;108:287-9.

  2. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-80.

  3. Berg M, Lindberg M. Possible gender differences in the quality of life and choice of therapy in acne. J Eur Acad Dermatol Venereol. 2011;25:969-72.

  4. Youn SH, Choi CW, Choi JW, Youn SW. The skin surface pH and its different influence on the development of acne lesion according to gender and age. Skin Res Technol. 2013;19:131-6.

  5. Kim BY, Choi JW, Park KC, Youn SW. Sebum, acne, skin elasticity, and gender difference - which is the major influencing factor for facial pores?. Skin Res Technol. 2013;19:e45-53.

  6. Harper JC. The efficacy and tolerability of a fixed combination clindamycin (12%) and benzoyl peroxide (375%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2015;14:381-4.

  7. Harper JC. Gender as a clinically relevant outcome variable in acne: benefits of a fixed combination clindamycin phosphate (12%) and benzoyl peroxide (25%) aqueous gel. J Drugs Dermatol. 2012;11:1440-5.

  8. Ockenfels HM, Uter W, Lessmann H, Schnuch A, Geier J. Patch testing with benzoyl peroxide: reaction profile and interpretation of positive patch test reactions. Contact Dermatitis. 2009;61:209-16.

  9. Thevarajah S, Balkrishnan R, Camacho FT, Feldman SR, Fleischer AB. Trends in prescription of acne medication in the US: shift from antibiotic to non-antibiotic treatment. J Dermatolog Treat. 2005;16:224-8.

  10. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]

  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]

  1. Lello J, Pearl A, Arroll B, Yallop J, Birchall NM. Prevalence of acne vulgaris in Auckland senior high school students. N Z Med J. 1995;108:287-9.
  2. Goulden V, Stables GI, Cunliffe WJ. Prevalence of facial acne in adults. J Am Acad Dermatol. 1999;41:577-80.
  3. Berg M, Lindberg M. Possible gender differences in the quality of life and choice of therapy in acne. J Eur Acad Dermatol Venereol. 2011;25:969-72.
  4. Youn SH, Choi CW, Choi JW, Youn SW. The skin surface pH and its different influence on the development of acne lesion according to gender and age. Skin Res Technol. 2013;19:131-6.
  5. Kim BY, Choi JW, Park KC, Youn SW. Sebum, acne, skin elasticity, and gender difference - which is the major influencing factor for facial pores?. Skin Res Technol. 2013;19:e45-53.
  6. Harper JC. The efficacy and tolerability of a fixed combination clindamycin (12%) and benzoyl peroxide (375%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2015;14:381-4.
  7. Harper JC. Gender as a clinically relevant outcome variable in acne: benefits of a fixed combination clindamycin phosphate (12%) and benzoyl peroxide (25%) aqueous gel. J Drugs Dermatol. 2012;11:1440-5.
  8. Ockenfels HM, Uter W, Lessmann H, Schnuch A, Geier J. Patch testing with benzoyl peroxide: reaction profile and interpretation of positive patch test reactions. Contact Dermatitis. 2009;61:209-16.
  9. Thevarajah S, Balkrishnan R, Camacho FT, Feldman SR, Fleischer AB. Trends in prescription of acne medication in the US: shift from antibiotic to non-antibiotic treatment. J Dermatolog Treat. 2005;16:224-8.
  10. Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.]
  11. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]
A A
A A

Klindamycin Testmiljö

Klindamycin

Klass : A

Visa all info

Skriv ut

Kontakta oss

  1. del Carmen Carrasco-Portugal M, Luján M, Flores-Murrieta FJ. Evaluation of gender in the oral pharmacokinetics of clindamycin in humans. Biopharm Drug Dispos. 2008;29:427-30.

  2. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999

  3. DALACIN (clindamycin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA); 2015.

  4. Harper JC. The efficacy and tolerability of a fixed combination clindamycin (12%) and benzoyl peroxide (375%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2015;14:381-4.

  5. Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71:18-26.

  6. Martindale: The Complete Drug Reference. Pharmaceutical Press.

  7. Swartzberg JE, Maresca RM, Remington JS. Clinical study of gastrointestinal complications associated with clindamycin therapy. J Infect Dis. 1977;135 Suppl:S99-103.

  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]

  1. del Carmen Carrasco-Portugal M, Luján M, Flores-Murrieta FJ. Evaluation of gender in the oral pharmacokinetics of clindamycin in humans. Biopharm Drug Dispos. 2008;29:427-30.
  2. Dollery C Sir, editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone; 1999
  3. DALACIN (clindamycin). Summary of Product Characteristics. Swedish Medical Products Agency (MPA); 2015.
  4. Harper JC. The efficacy and tolerability of a fixed combination clindamycin (12%) and benzoyl peroxide (375%) aqueous gel in patients with facial acne vulgaris: gender as a clinically relevant outcome variable. J Drugs Dermatol. 2015;14:381-4.
  5. Fernandez-Obregon A, Davis MW. The BEST study: evaluating efficacy by selected demographic subsets. Cutis. 2003;71:18-26.
  6. Martindale: The Complete Drug Reference. Pharmaceutical Press.
  7. Swartzberg JE, Maresca RM, Remington JS. Clinical study of gastrointestinal complications associated with clindamycin therapy. J Infect Dis. 1977;135 Suppl:S99-103.
  8. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-06-30.]